Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Total Current Liabilities
All obligations due within one year.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities falls 12.9% from a year ago
Total current liabilities stood at $19.32M at the end of Q2 FY2026, down 12.9% from a year earlier and up 31.3% from the prior quarter. Over 3 fiscal years it compounded at +23.3% a year.
Context
- Total current liabilities amounted to 2.9% of total assets at the end of Q2 FY2026, down 3.7 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -12.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 15.11M USD
- Year-over-year change
- +3.2%
- 4-year CAGR
- +31.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.11M | +3.2% |
| FY2024 | 2024-12-31 | 14.65M | +39.7% |
| FY2023 | 2023-12-31 | 10.48M | +29.9% |
| FY2022 | 2022-12-31 | 8.07M | +59.6% |
| FY2021 | 2021-12-31 | 5.05M | — |
Total Current Liabilities vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's Jun 2026 total current liabilities of $19.32M is the 5th highest of the 7 companies compared; the peer median is $23.86M.
- Its year-over-year change of -12.9% is the lowest of 7, against a peer median of +33.6%.
- Total current liabilities amounts to 2.9% of total assets for MLYS, versus a peer median of 12.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $210.91M | +56.1% | +4.0% | 24.9% | |
| Jun 2026 | $48.32M | +44.0% | +27.8% | 9.1% | |
| Mar 2026 | $26.49M | +58.8% | +79.3% | 41.1% | |
| Mar 2026 | $21.24M | +14.1% | +2.8% | 5.1% | |
| Jun 2026 | $19.32M | -12.9% | +23.3% | 2.9% | |
| Mar 2026 | $13.69M | -11.6% | -3.4% | 13.6% | |
| Mar 2026 | $5.75M | +23.2% | +33.3% | 10.8% | |
| Peer median (excluding MLYS) | $23.86M | +33.6% | +15.9% | 12.2% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10.61M | 87.7M | 49.3M | 114.09M | 172.92M |
| Short-term Investments | 0 | 22.41M | 187.26M | 84.1M | 483.71M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 50K | 2.7M | 12.54M | 7.16M | 4.75M |
| Total Current Assets | 11.12M | 112.81M | 249.1M | 205.35M | 661.39M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 53K | 38K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 2.48M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3K | 1.63M | 51K | 499K | 382K |
| Total Non-current Assets | 3K | 1.63M | 2.53M | 552K | 420K |
| Total Assets | 11.13M | 114.44M | 251.64M | 205.9M | 661.81M |
| Account Payables | 763K | 1.91M | 601K | 479K | 2.02M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 313K | 665K | 1.6M | 3.58M | 7.56M |
| Total Current Liabilities | 5.05M | 8.07M | 10.48M | 14.65M | 15.11M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 29M | 158.64M | 0 | 0 | 0 |
| Total Non-current Liabilities | 29M | 158.64M | 0 | 0 | 0 |
| Total Liabilities | 34.05M | 166.71M | 10.48M | 14.65M | 15.11M |
| Common Stock | 1K | 1K | 4K | 5K | 8K |
| Retained Earnings | (23.01M) | (52.81M) | (124.71M) | (302.52M) | (457.17M) |
| Accumulated OCI | 0 | 0 | (251.64M) | 0 | 0 |
| Other Stockholders Equity | (29M) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (22.93M) | (52.27M) | 241.15M | 191.26M | 646.69M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (10.61M) | (87.7M) | (49.3M) | (114.09M) | (172.92M) |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.